Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Mar;29(3):387-93.
doi: 10.1007/s00384-013-1807-5. Epub 2013 Dec 18.

Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis--a prospective randomized study

Lukasz Krokowicz  1 , Zoran Stojcev, Bartosz Filip Kaczmarek, Wojciech Kociemba, Elżbieta Kaczmarek, Jaroslaw Walkowiak, Piotr Krokowicz, Michal Drews, Tomasz Banasiewicz
Affiliations
Randomized Controlled Trial

Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis--a prospective randomized study

Lukasz Krokowicz et al. Int J Colorectal Dis. 2014 Mar.

Abstract

Background: Microencapsulated sodium butyrate (MSB) has been previously associated with anti-inflammatory and regenerative properties regarding large bowel mucosa. We aimed to examine a role of MSB in patients with diverticulosis, hypothesizing its potential for reduction of diverticulitis episodes and diverticulitis prevention.

Methods: Seventy-three patients with diverticulosis (diagnosed in colonoscopy or/and barium enema or/and CT colography) were recruited for the study and randomized. The investigated group was administered MSB 300 mg daily; the control group was administered placebo. After 12 months, a total of 52 patients completed the study and were subject to analysis (30 subjects and 22 controls). During the study, the number of episodes of diverticulitis (symptomatic diagnosis with acute pain, fever, and leukocytosis), hospitalizations, and surgery performed for diverticulitis were recorded. Additionally, a question regarding subjective improvement of symptoms reflected changes in quality of life during the analysis.

Results: After 12 months, the study group noted a significantly decreased number of diverticulitis episodes in comparison to the control group. The subjective quality of life in the study group was higher than in the control group. There were no side effects of the MSB during the therapy.

Conclusions: MSB reduces the frequency of diverticulitis episodes, is safe, and improves the quality of life. It can play a role in the prevention of diverticulitis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart representing the course double-blinded randomized study
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Parks TG. Natural history of diverticular disease of the colon. Clin Gastroenterol. 1975;4:3–21. - PubMed
    1. Floch MH, Bina I. The natural history of diverticulitis: fact and theory. J Clin Gastroenterol. 2004;38:S2–S7. doi: 10.1097/01.mcg.0000124003.07433.ee. - DOI - PubMed
    1. Munson KD, Hensien MA, Jacob LN, Robinson AM, Liston WA. Diverticulitis: a comprehensive follow-up. Dis Colon Rectum. 1996;39:318–324. doi: 10.1007/BF02049475. - DOI - PubMed
    1. World Medical Association (2008) WMA Declaration of Helsinki—ethical principles for medical research involving human subjects, Seoul, Korea
    1. Mizuki A, Nagata H, Tatemichi M, Kaneda S, Tsukada N, Ishii H, Hibi T. The out-patient management of patients with acute mild-to-moderate colonic diverticulitis. Aliment Pharmacol Ther. 2005;21:889–897. doi: 10.1111/j.1365-2036.2005.02422.x. - DOI - PubMed

Publication types